Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
RKV(RKV) VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Executive Chairman, Jeffrey Bacha, and Chief Financial Officer, Dr. David Kideckel, will attend and present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8th-10th in New York City.
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
RKVVANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Chief Scientific Officer Dr. Mads Daugaard has been invited to present this week at the 13th Tuscany Retreat on Cancer Research and Apoptosis: Genetic profiling, resistance mechanisms and novel treatment concepts in cancer and neurodegeneration, taking place August 23-30 in Tuscany, Italy.
